AbbVie’s Aquipta becomes the first oral CGRP migraine drug
By Son, Hyung-Min | translator Kang, Shin-Kook
24.05.13 05:03:49
가나다라
0
Aquipta found to reduce the average number of monthly migraine days in 3 trials
Treatment choices expanded, but strict reimbursement criteria remain a challenge...' needs improvement’
▲Professor Byung-Kun Kim (Department of Neurology, Nowon Eulji Medical Center)
For the first time, an oral CGRP drug has been introduced for the treatment of migraine. AbbVie’s Aquipta has shown positive results as a preventive treatment for chronic migraine as well as episodic migraine in patients who have failed up to 4 prior oral preventive treatments. Experts believe that the benefits of being an oral formulation would allow Aquipta to become a viable new treatment option that can meet the unmet needs of migraine patients in Korea.On the 10th, AbbVie Korea held a press conference to celebrate the launch of Aquipta, its oral calcitonin gene-related peptide (GRRP) receptor agonist, in Korea. Aquipta was approved in Korea last November for migraines in adults.
T
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)